Avaliação da eficácia e segurança das principais vacinas utilizadas contra COVID-19 no Brasil / Evaluation of the efficacy and safety of the main vaccines used against COVID-19 in Brazil
DOI:
https://doi.org/10.34117/bjdv8n4-588Keywords:
vacina COVID-19, eficácia, segurança.Abstract
O surgimento da síndrome respiratória aguda grave causada pelo novo coronavírus (SARS-CoV-2) teve devastadoras consequências mundiais. Sendo assim, a pesquisa e produção de vacinas eficazes e seguras foram necessárias para prevenir a Covid-19 e também para proteger os indivíduos que estivessem sob alto risco de complicações. O objetivo do presente estudo foi buscar na literatura científica a eficácia e segurança das principais vacinas utilizadas no Brasil. Uma revisão sistemática foi realizada, no qual buscou-se artigos científicos indexados no Scielo, PubMed e ScienseDirect, utilizando os seguintes descritores: COVID-19 vaccines, effectiveness e safety. Foram introduzidos nesta revisão 15 artigos dentre os 419 encontrados nas bases de dados. As principais vacinas utilizadas no Brasil para a COVID-19 foram: Pfizer/BioNTech (BNT162b2), AstraZenica/Oxford (ChAdOx1), Janssen/ Johnson & Johnson (Ad26.COV2.S) e CoronaVac/Sinovak Life Sciences. Os estudos demonstram que todas as vacinas distribuídas e administradas no Brasil possuem alta eficácia e segurança por terem a capacidade de proteger os vacinados contra a Covid-19, aumentando as respostas das células de defesas específicas, diminuindo o índice de mortalidade em pacientes que contraem o SARS-CoV-2, bem como também possuem reações adversas toleráveis aos imunizados.
References
CASTRO, Rosana. Vacinas contra a Covid-19: o fim da pandemia?. 2021.
CARVALHO, Jóni Costa et al. Hypersensitivity Reactions to Vaccines: Current Evidence and Standards for SARS-CoV-2 Vaccines. Acta Médica Portuguesa, v. 34, n. 13, 2021.
COVID-19 Vacinação Doses Aplicadas. Ministério da Saúde, 2021. Disponível em: < https://www.gov.br/saude/pt-br/vacinacao> Acesso em: 17 de nov. de 2021
DE ARAÚJO, Igor Gomes et al. Imunopatologia do SARS-CoV-2 e análise dos imunizantes no território brasileiro. Revista de Casos e Consultoria, v. 12, n. 1, p. e23990-e23990, 2021.
DA PAZ SILVA FILHO, Paulo Sérgio et al. Vacinas contra Coronavírus (COVID-19; SARS-COV-2) no Brasil: um panorama geral. Research, Society and Development, v. 10, n. 8, p. e26310817189-e26310817189, 2021.
FARMACÊUTICA, Janssen-Cilag. Vacina covid-19 (recombinante): suspensão para injeção: Janssen. 2020.
PEREIRA, Adriana Soares et al. Metodologia da pesquisa científica. 2018.
LIBERATI, Alessandro et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of clinical epidemiology, v. 62, n. 10, p. e1-e34, 2009.
MATHIEU, E. et al. A global database of COVID-19 vaccinations. Nat Hum Behav, 2021.
POLACK, Fernando P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 2020.
WALSH, Edward E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine, v. 383, n. 25, p. 2439-2450, 2020.
LV, Meng et al. Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review. Vaccines, v. 9, n. 10, p. 1102, 2021.
FRENCK JR, Robert W. et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine, 2021.
KOW, Chia Siang; HASAN, Syed Shahzad. Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies. Inflammopharmacology, v. 29, n. 4, p. 1075-1090, 2021.
BOROBIA, Alberto M. et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet, v. 398, n. 10295, p. 121-130, 2021.
KADALI, Renuka AK et al. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. International Journal of Infectious Diseases, v. 106, p. 376-381, 2021.
FOLEGATTI, Pedro M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet, v. 396, n. 10249, p. 467-478, 2020.
VOYSEY, Merryn et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, v. 397, n. 10269, p. 99-111, 2021.
RAMASAMY, Maheshi N. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet, v. 396, n. 10267, p. 1979-1993, 2020.
MADHI, Shabir A. et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant. New England Journal of Medicine, v. 384, n. 20, p. 1885-1898, 2021.
SADOFF, Jerald et al. Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19. New England Journal of Medicine, v. 384, n. 23, p. 2187-2201, 2021.
WHO Coronavirus (COVID-19) Dashboard. World Health Organization, 2021. Disponível em: <https://covid19.who.int/> Acesso em: 17 de nov. de 2021.
YUAN, Ping et al. Safety, tolerability, and immunogenicity of COVID-19 vaccines: a systematic review and meta-analysis. medRxiv, 2020.
CAI, Changjing et al. A comprehensive analysis of the efficacy and safety of COVID-19 vaccines. Molecular Therapy, v. 29, n. 9, p. 2794-2805, 2021.
KAUR, Rimple Jeet et al. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Indian Journal of Clinical Biochemistry, p. 1-13, 2021.
